Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Rivaroxaban inhibits Factor Xa, whereas VKAs inhibit the glycosylation of multiple vitamin K-dependent coagulation proteins. TF: Tissue factor; VKA: Vitamin K antagonist.

The results of the Regulation of Coagulation in Major Orthopedic Surgery Reducing the Risk of DVT and PE (RECORD) studies showed that rivaroxaban is more effective than enoxaparin in the ...

rivaroxaban, 0.38 [95% confidence interval {CI}, 0.24 to 0.60]; hazard ratio for 90-mg abelacimab vs. rivaroxaban, 0.31 [95% CI, 0.19 to 0.51]; P<0.001 for both comparisons). The incidence and ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...